A review of a new salt that can be used to treat nicotine addiction has been published in The Lancet.
The study examined the effects of three salt formulations on nicotine-dependent patients, with a focus on nicotine as the main ingredient.
Dr. Peter Brierly, a psychiatrist at the Yale School of Medicine, is one of the authors of the study, which will be presented at the American Psychiatric Association annual meeting in Washington, DC, later this month.
He is also a co-author of the recently published paper, “The effects of nicotine salt on nicotine dependence in smokers.”
Dr. Briersley’s findings are similar to that of another Yale team.
The researchers used a similar design to look at the effects on nicotine addiction of a novel nicotine salt, Nic-100, and found that the drug has a similar effect on nicotine use as Nic-1, which is a less-expensive nicotine salt.
The researchers also found that Nic-150 is effective in reducing nicotine addiction.
Dr. Wrenn F. Beil, Ph.
D., chair of the department of psychiatry at New York University School of Health, is the lead author of the paper.
He noted that the new salt has been developed specifically to be used for nicotine addiction and not for other disorders.
Nicotine is a key chemical in the brain, and is involved in a number of physiological functions, including pain and pleasure.
In the United States, tobacco smoking kills about 5 million people annually, and about one in five people who use tobacco smoke are addicted to nicotine.
In the study of Nic-50, which was also conducted at New England Baptist Medical Center, the researchers found that it was a better choice for people who are trying to quit smoking than Nic-2, which has a lower potency.
But Nic-5, which had a higher nicotine content, was not as effective as Nic+ for reducing nicotine dependence.
Nic-100 was also tested in the study.
In that study, the patients were given either Nic-60, Nic+ or Nic-200 for five weeks.
In addition, the team used an alternative nicotine salt called Nic-300.
The salt was also given to the patients for two weeks to determine if it had an effect.
The results of the trials showed that Nic+ was more effective than Nic-.
In fact, the nicotine levels in the patients who were given Nic-160 had decreased by more than half compared to the nicotine-using patients.
Nic− was less effective than both Nic-20 and Nic-30.
In contrast, the levels of nicotine in Nic-120 and Nic+120 were similar to those in Nic+, and the amount of nicotine decreased by less than half in the nicotine dependent patients who received Nic-80.
However, in a third trial, a more comprehensive study, Nic– was more than twice as effective than the other two nicotine salts, which also had similar effects on reducing nicotine withdrawal symptoms.
In terms of how long a person needed to take Nic-to-be to be effective, Nic− was about 15 to 20 minutes compared to Nic+ about 12 minutes.
Nic-40 was the longest, at about an hour.
However, the study did not include patients who had been smoking for a while.
Dr. Beileil said that there is currently no data on whether people who have been using nicotine for years and who have taken other medications may be more successful in using Nic- to be.